Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 25;13:269. doi: 10.1038/s41398-023-02564-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — A Experimental protocol. Mice were i.p. injected with LPS (0.1 mg/kg) or saline (10 ml/kg). 5-ALA (300 mg/kg/day) or vehicle (10 ml/kg/day) was administered orally to mice for consecutive 3 days before LPS injection. Locomotion test and forced swimming test (FST) were performed 23 and 24 h after the injection of saline or LPS, respectively. Blood and spleens were collected after behavioral tests. B Body weight change (one-way ANOVA: F_2,28 = 120.50, P < 0.0001). C Locomotion test (one-way ANOVA: F_2,28 = 0.521, P = 0.599). D FST (one-way ANOVA: F_2,28 = 6.063, P = 0.006). E Spleen weight (one-way ANOVA: F_2,28 = 41.29, P < 0.0001). F Plasma levels of TNF-α (one-way ANOVA: F_2,28 = 40.05, P < 0.0001). G Plasma levels of IL-6 (one-way ANOVA: F_2,28 = 5.573, P = 0.009). H There was a positive correlation (R = 0.7380, P < 0.0001) between spleen weight and plasma TNF-α. I There was a positive correlation (R = 0.7026, P < 0.0001) between spleen weight and plasma IL-6. J Alas2 mRNA in the spleen (one-way ANOVA: F_2,28 = 15.77, P < 0.0001). K Fech mRNA in the spleen (one-way ANOVA: F_2,28 = 11.82, P = 0.0002). L Hmbs mRNA in the spleen (one-way ANOVA: F_2,28 = 10.93, P = 0.0003). The data represent mean ± S.E.M. (n = 10 or 11). ^*P < 0.05, ^**P < 0.01, ^***P < 0.001. N.S., not significant.